Skip to main content

Table 2 General characteristics of study subjects participating in KNOW-CKD from 2011 to September, 2013

From: KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods

 

Total cohort1

Subcohort

 

GN

DN

HTN

PKD

p-value2

Total participants from 2011 to 2013

1470

543

317

294

249

 

Age

53.6 ± 12.3

50 ± 12.3

59.2 ± 9.3

59.6 ± 10.9

46.9 ± 10.4

< 0.001

Female

569 (38.7)

228 (42)

104 (32.8)

82 (27.9)

127 (51)

< 0.001

BMI (kg/m2)

24.4 ± 3.4

24.2 ± 3.4

25.2 ± 3.2

24.8 ± 3.5

23.5 ± 3.1

< 0.001

Waist-Hip ratio

0.89 ± 0.07

0.88 ± 0.07

0.92 ± 0.05

0.9 ± 0.07

0.88 ± 0.06

< 0.001

SBP (mmHg)

127.7 ± 16.5

123.2 ± 14.9

135.8 ± 18.7

127 ± 16.4

128 ± 13.5

< 0.001

DBP (mmHg)

76.6 ± 11.1

75.2 ± 10.6

76.1 ± 11.8

76.8 ± 11.6

79.8 ± 10.2

< 0.001

Pulse Pressure (mmHg)

51.1 ± 12.1

48 ± 10.6

59.7 ± 12.9

50.2 ± 11.5

48.2 ± 9.5

< 0.001

CKD stage 1

160 (10.9)

81 (14.9)

4 (1.3)

2 (0.7)

63 (25.3)

< 0.001

      2

253 (17.2)

117 (21.5)

18 (5.7)

18 (6.1)

79 (31.7)

 

      3a

268 (18.2)

111 (20.4)

45 (14.2)

67 (22.8)

35 (14.1)

 

      3b

328 (22.3)

110 (20.3)

83 (26.2)

91 (31)

30 (12)

 

      4

349 (23.7)

93 (17.1)

121 (38.2)

95 (32.3)

30 (12)

 

      5

112 (7.6)

31 (5.7)

46 (14.5)

21 (7.1)

12 (4.8)

 

Creatinine (mg/dL)

1.88 ± 1.17

1.67 ± 1.08

2.48 ± 1.38

2.12 ± 1.00

1.40 ± 0.98

< 0.001

Cystatin C (mg/L)

1.81 ± 0.95

1.61 ± 0.89

2.37 ± 0.99

2.04 ± 0.83

1.34 ± 0.79

< 0.001

eGFR (mL/min/1.73 m2)

      

  MDRD

48.6 ± 29.4

54.9 ± 30.6

32.7 ± 17.9

36.6 ± 17.4

67 ± 33.9

< 0.001

  CKD-EPI cr (2009)

51.4 ± 30.3

58.3 ± 31

34 ± 19.5

37.9 ± 17.7

71.8 ± 33.6

< 0.001

Comorbid disease

      

  Coronary artery disease

107 (7.3)

22 (4.1)

44 (14.1)

32 (10.9)

3 (1.2)

< 0.001

  Peripheral vascular disease

22 (1.5)

2 (0.4)

10 (3.2)

9 (3.1)

0 (0)

< 0.001

  Cerebrovascluar disease

125 (8.5)

21 (3.9)

37 (11.9)

34 (11.6)

29 (11.6)

< 0.001

  Diabetes

462 (31.6)

56 (10.4)

317 (100)

61 (20.7)

3 (1.2)

< 0.001

  Hypertension

1325 (90.6)

470 (86.9)

302 (96.8)

283 (96.3)

213 (85.5)

< 0.001

  Chronic heart failure

15 (1)

3 (0.6)

8 (2.6)

4 (1.4)

0 (0)

0.011

  Arrhythmia

31 (2.1)

8 (1.5)

6 (1.9)

12 (4.1)

3 (1.2)

0.049

Cardiac parameters

      

  AAC score

1.2 ± 2.6

0.7 ± 1.9

2.6 ± 3.7

1.3 ± 2.7

0.3 ± 1.3

< 0.001

  Mean baPWV (cm/s)

1525.0 ± 342.5

1396.4 ± 245.8

1819.2 ± 418.2

1569.1 ± 297.7

1392 ± 213.2

< 0.001

  LVMI (g/m2) (Echocardiography)

95.0 ± 28.4

89.5 ± 25.2

106.5 ± 30.7

100.6 ± 31.9

85.9 ± 20.1

< 0.001

  Coronary Ca score

191.7 ± 569.6

91.6 ± 409.9

496.3 ± 864.6

195.6 ± 569.5

28.5 ± 133.1

< 0.001

  Troponin T (ng/mL)

0.016 ± 0.018

0.011 ± 0.010

0.030 ± 0.030

0.016 ± 0.011

0.008 ± 0.004

< 0.001

  Valve calcification (Echocardiography)

262 (18.5)

105 (20.2)

82 (27.1)

65 (23)

7 (2.8)

< 0.001

  1. 1Total participants included those in 4 subgroups and the other unclassified kidney diseases.
  2. ANOVA or Kruskal-Wallis test for continuous variables and Chi-square or Fisher’s Exact test for categorical variables.
  3. Numbers denote mean ± s.d. or number (%).
  4. Abbreviations: GN, glomerulonephropathy; DN , diabetic nephropathy; HTN, hypertensive nephropathy; PKD, autosomal dominant polycystic kidney disease; AAC, abdominal aorta calcification; baPWV, brachial-to-ankle pulse wave velocity; LVMI, left ventricular mass index.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us